Literature DB >> 19396865

Frequent upregulation of MYC in plasma cell leukemia.

Laura Chiecchio1, Gian Paolo Dagrada, Helen E White, Mark R Towsend, Rebecca K M Protheroe, Kan Luk Cheung, David M Stockley, Kim H Orchard, Nicholas C P Cross, Christine J Harrison, Fiona M Ross.   

Abstract

Plasma cell leukemia (PCL) is a rare form of monoclonal gammopathy, which can originate de novo or evolve from multiple myeloma (MM) as a terminal leukemic phase. Previous cytogenetic studies of PCL have reported the presence of complex karyotypes with involvement of multiple unidentified chromosomal regions. We report here the analysis of 12 PCL (10 primary and two secondary) by metaphase and FISH analysis combined with oligonucleotide array data (244 k, Agilent). Interphase-FISH results were compared with those from a series of 861 newly diagnosed patients with MM. Cytogenetic analysis was successful on 11 patients, all of whom showed clonal chromosomal abnormalities. Compared with MM, t(11;14)(q13;q32) (42% versus 15%; P = 0.027) and t(14;16)(q32;q23) (25% versus 4%; P = 0.010) were more frequent in PCL, although neither the specific partner chromosome involved in the IgH translocation nor the ploidy status predicted for survival. Chromosomes 1, 8, 13, and 16 showed the highest number of copy number alterations with 8q24 being the chromosomal region most frequently involved. In eight of 12 patients we found abnormalities (translocations, one amplification, small deletions, and duplications) that directly targeted or were very close to MYC. Only four of these changes were detected by routine FISH analysis using commercial probes with the others exclusively detected by arrays. Quantitative reverse transcription polymerase chain reaction demonstrated that these different abnormalities were associated with increased levels of MYC mRNA. We conclude that MYC dysregulation by complex mechanisms is one of the major molecular events in the oncogenesis of PCL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396865     DOI: 10.1002/gcc.20670

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

1.  Plasma cell leukemia.

Authors:  Moria A Gertz; Francis K Buadi
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

Review 2.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

3.  Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.

Authors:  Isabella C Glitza; Gary Lu; Rupin Shah; Qaiser Bashir; Nina Shah; Richard E Champlin; Jatin Shah; Robert Z Orlowski; Muzaffar H Qazilbash
Journal:  Leuk Lymphoma       Date:  2014-08-18

4.  Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.

Authors:  Gary Lu; Ramya Muddasani; Robert Z Orlowski; Lynne V Abruzzo; Muzaffar H Qazilbash; M James You; Yaping Wang; Ming Zhao; Su Chen; Isabella Claudia Glitza; L Jeffrey Medeiros
Journal:  Arch Pathol Lab Med       Date:  2013-05       Impact factor: 5.534

Review 5.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

6.  Myc roles in hematopoiesis and leukemia.

Authors:  M Dolores Delgado; Javier León
Journal:  Genes Cancer       Date:  2010-06

Review 7.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 8.  Primary Plasma Cell Leukemia: Identity Card 2016.

Authors:  Pellegrino Musto; Vittorio Simeon; Katia Todoerti; Antonino Neri
Journal:  Curr Treat Options Oncol       Date:  2016-04

9.  Glucocorticoid receptor expression in multiple myeloma patients is a predictor of survival.

Authors:  Alexander Pozhitkov; Michael Rosenzweig; Flavia Pichiorri; Emine G Gunes; Ralf Buettner; Jonathan J Keats; Steven T Rosen
Journal:  Leuk Lymphoma       Date:  2020-09-13

10.  Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents.

Authors:  Giampaolo Talamo; Nathan G Dolloff; Kamal Sharma; Junjia Zhu; Jozef Malysz
Journal:  Rare Tumors       Date:  2012-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.